IL33 and liver disorder: Because both NLRP3 and IL-33 pathways are engaged in sterile inflammation-associated liver disease [48], we assessed their expression in Atg9a-cKO livers and found elevated inflammatory markers (Figure 2C) despite no overt fibrosis or apoptosis (Figure 2A,B, Supp.